BR112017004589A2 - composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd - Google Patents
composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smydInfo
- Publication number
- BR112017004589A2 BR112017004589A2 BR112017004589A BR112017004589A BR112017004589A2 BR 112017004589 A2 BR112017004589 A2 BR 112017004589A2 BR 112017004589 A BR112017004589 A BR 112017004589A BR 112017004589 A BR112017004589 A BR 112017004589A BR 112017004589 A2 BR112017004589 A2 BR 112017004589A2
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- compound
- kit
- patient
- pharmaceutical composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000003053 piperidines Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 101150027702 smyd2-a gene Proteins 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462048771P | 2014-09-10 | 2014-09-10 | |
| US201462078845P | 2014-11-12 | 2014-11-12 | |
| US201562146790P | 2015-04-13 | 2015-04-13 | |
| PCT/US2015/049235 WO2016040515A1 (en) | 2014-09-10 | 2015-09-09 | Substituted piperidine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017004589A2 true BR112017004589A2 (pt) | 2018-01-23 |
Family
ID=55459535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017004589A BR112017004589A2 (pt) | 2014-09-10 | 2015-09-09 | composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10577363B2 (enExample) |
| EP (1) | EP3193605A4 (enExample) |
| JP (1) | JP2017528464A (enExample) |
| KR (1) | KR20170047397A (enExample) |
| CN (1) | CN107072207A (enExample) |
| AU (1) | AU2015315182A1 (enExample) |
| BR (1) | BR112017004589A2 (enExample) |
| CA (1) | CA2960280A1 (enExample) |
| EA (1) | EA201790327A1 (enExample) |
| IL (1) | IL250888A0 (enExample) |
| MX (1) | MX2017002986A (enExample) |
| SG (2) | SG10201901189SA (enExample) |
| WO (1) | WO2016040515A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102496364B1 (ko) | 2014-09-10 | 2023-02-06 | 에피자임, 인코포레이티드 | Ｓｍｙｄ 억제제 |
| JP2017526706A (ja) | 2014-09-10 | 2017-09-14 | エピザイム，インコーポレイティド | イソオキサゾールカルボキサミド化合物 |
| AU2015315171A1 (en) | 2014-09-10 | 2017-03-16 | Epizyme, Inc. | Substituted cyclohexylamine compounds |
| JP2017528460A (ja) * | 2014-09-10 | 2017-09-28 | エピザイム インコーポレイテッド | 不可逆的ｓｍｙｄ阻害剤としてのイソオキサゾールカルボキサミド |
| EP3263572B1 (en) | 2015-02-27 | 2021-12-15 | Seed Research Institute Co., Ltd. | Method for producing kakeromycin and derivatives thereof |
| HUE057315T2 (hu) * | 2016-07-28 | 2022-04-28 | Idorsia Pharmaceuticals Ltd | Piperidin cxcr7 receptor modulátorok |
| WO2018151678A1 (en) * | 2017-02-15 | 2018-08-23 | Agency For Science, Technology And Research | Compounds for treatment of cancer and epigenetics |
| MA51664B1 (fr) * | 2018-01-26 | 2024-05-31 | Idorsia Pharmaceuticals Ltd | Formes cristallines de l'antagoniste du récepteur cxcr7 d'acide (3s,4s)-1-cyclopropylméthyl-4-([5-(2,4-difluoro-phényl)-isoxazole-3-carbonyl]-amino)-pipéridine-3-carboxylique (1-pyrimidin-2-yl-cyclopropyl)-amide |
| CN112955214B (zh) | 2018-10-29 | 2024-05-07 | 勃林格殷格翰国际有限公司 | 吡啶基磺酰胺衍生物、药物组合物及其用途 |
| FI3873600T3 (fi) | 2018-10-29 | 2023-12-07 | Boehringer Ingelheim Int | Pyridinyylisulfonamidijohdannaisia, farmaseuttisia koostumuksia ja niiden käytöt |
| JP7678756B2 (ja) | 2019-09-30 | 2025-05-16 | 日本ケミファ株式会社 | アゼパン誘導体 |
| CN114702552B (zh) * | 2022-03-11 | 2024-05-31 | 苏州思萃免疫技术研究所有限公司 | mTORC2抑制剂 |
| CN117800895A (zh) * | 2022-09-30 | 2024-04-02 | 苏州阿尔脉生物科技有限公司 | 草酸胺类衍生物、包含其的药物组合物及其医药用途 |
| WO2025133989A1 (en) * | 2023-12-20 | 2025-06-26 | Alt-Bio Pte. Ltd. | Smyd modulators and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1228288B (it) * | 1989-01-09 | 1991-06-07 | Zambon Spa | Composti ad attivita' antiserotoninica |
| SE9902987D0 (sv) | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
| SE0403106D0 (sv) * | 2004-12-20 | 2004-12-20 | Astrazeneca Ab | Chemical compounds |
| WO2008137834A2 (en) * | 2007-05-04 | 2008-11-13 | Osi Pharmaceuticals, Inc. | Crystal structure of smyd3 protein |
| PE20091093A1 (es) * | 2007-12-03 | 2009-08-25 | Takeda Pharmaceutical | Compuesto heterociclico que contiene nitrogeno y su uso |
| TWI535712B (zh) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
| US9045485B2 (en) * | 2010-12-16 | 2015-06-02 | Convergence Pharmaceuticals Limited | ASK 1 inhibiting pyrrolopyrimidine derivatives |
| JP2017528460A (ja) * | 2014-09-10 | 2017-09-28 | エピザイム インコーポレイテッド | 不可逆的ｓｍｙｄ阻害剤としてのイソオキサゾールカルボキサミド |
| KR102496364B1 (ko) | 2014-09-10 | 2023-02-06 | 에피자임, 인코포레이티드 | Ｓｍｙｄ 억제제 |
| AU2015315171A1 (en) | 2014-09-10 | 2017-03-16 | Epizyme, Inc. | Substituted cyclohexylamine compounds |
| US20170247326A1 (en) | 2014-09-10 | 2017-08-31 | Epizyme, Inc. | Substituted Pyrrolidine Carboxamide Compounds |
| JP2017526706A (ja) * | 2014-09-10 | 2017-09-14 | エピザイム，インコーポレイティド | イソオキサゾールカルボキサミド化合物 |
| US20170253601A1 (en) | 2014-09-10 | 2017-09-07 | Epizyme, Inc. | Substituted Pyrrolidine Compounds |
-
2015
- 2015-09-09 MX MX2017002986A patent/MX2017002986A/es unknown
- 2015-09-09 AU AU2015315182A patent/AU2015315182A1/en not_active Abandoned
- 2015-09-09 SG SG10201901189SA patent/SG10201901189SA/en unknown
- 2015-09-09 JP JP2017513207A patent/JP2017528464A/ja active Pending
- 2015-09-09 BR BR112017004589A patent/BR112017004589A2/pt not_active Application Discontinuation
- 2015-09-09 EP EP15840497.0A patent/EP3193605A4/en not_active Withdrawn
- 2015-09-09 CN CN201580060918.8A patent/CN107072207A/zh active Pending
- 2015-09-09 US US15/510,588 patent/US10577363B2/en active Active
- 2015-09-09 KR KR1020177009316A patent/KR20170047397A/ko not_active Withdrawn
- 2015-09-09 SG SG11201701597RA patent/SG11201701597RA/en unknown
- 2015-09-09 EA EA201790327A patent/EA201790327A1/ru unknown
- 2015-09-09 CA CA2960280A patent/CA2960280A1/en not_active Abandoned
- 2015-09-09 WO PCT/US2015/049235 patent/WO2016040515A1/en not_active Ceased
-
2017
- 2017-03-02 IL IL250888A patent/IL250888A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3193605A4 (en) | 2018-04-18 |
| SG11201701597RA (en) | 2017-03-30 |
| CN107072207A (zh) | 2017-08-18 |
| KR20170047397A (ko) | 2017-05-04 |
| EA201790327A1 (ru) | 2017-10-31 |
| JP2017528464A (ja) | 2017-09-28 |
| CA2960280A1 (en) | 2016-03-17 |
| WO2016040515A1 (en) | 2016-03-17 |
| US20170362217A1 (en) | 2017-12-21 |
| MX2017002986A (es) | 2017-10-24 |
| US10577363B2 (en) | 2020-03-03 |
| EP3193605A1 (en) | 2017-07-26 |
| AU2015315182A1 (en) | 2017-03-16 |
| SG10201901189SA (en) | 2019-03-28 |
| IL250888A0 (en) | 2017-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017004589A2 (pt) | composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd | |
| BR112018070859A2 (pt) | degradantes da proteína de bet | |
| BR112016008468A2 (pt) | Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer | |
| BR112019006712A2 (pt) | composto, composição farmacêutica, composição para uso no tratamento de uma doença, elemento implantável, e, dispositivo. | |
| MX2018003594A (es) | Anticuerpo anti-garp. | |
| CR20190318A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| BR112019022512A2 (pt) | Compostos de heteroarila bicíclica fundida 6-6 e seu uso como inibidores de lats | |
| MX2023006257A (es) | Inhibidores de smyd. | |
| BR112015016793A2 (pt) | compostos de tiazolacarboxamidas e piridinacarbo-xamida úteis como inibidores de quinase pim | |
| BR112016018555A8 (pt) | Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1 | |
| BR112014018990A8 (pt) | Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção | |
| MX2016012097A (es) | Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer. | |
| BR112016000489A8 (pt) | composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos | |
| BR112015026023A2 (pt) | derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1 | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| EA201891063A1 (ru) | Производные дигидроимидазопиразинона, применимые в лечении рака | |
| BR112016027041A8 (pt) | combinações farmacêuticas para tratamento do câncer | |
| NI201600176A (es) | Compuestos de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer. | |
| BR112019020421A8 (pt) | Derivados de 2-oxo- tiazóis como inibidores de a2a e compostos para uso no tratamento de cânceres | |
| BR112017001334A2 (pt) | compostos de imidazopiridazina, seu uso e composição farmacêutica que os compreende | |
| BR112017026535A2 (pt) | composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto | |
| BR112018007664A2 (pt) | antagonistas de ep4 | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| BR112018006545A2 (pt) | ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição? | |
| BR112018070536A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: A CLASSIFICACAO ANTERIOR ERA: A01N 43/80 Ipc: C07D 413/12 (2006.01), C07D 413/14 (2006.01), C07D |
|
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |